|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Henley SJ, Ward EM, Scott S, Ma J,
Anderson RN, Firth AU, Thomas CC, Islami F, Weir HK, Lewis DR, et
al: Annual report to the nation on the status of cancer, part I:
National cancer statistics. Cancer. 126:2225–2249. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu KH and Broaddus RR: Endometrial cancer.
N Engl J Med. 383:2053–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aoki Y, Kanao H, Wang X, Yunokawa M,
Omatsu K, Fusegi A and Takeshima N: Adjuvant treatment of
endometrial cancer today. Jpn J Clin Oncol. 50:753–765. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bestvina CM and Fleming GF: Chemotherapy
for endometrial cancer in adjuvant and advanced disease settings.
Oncologist. 21:1250–1259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Furuse M, Fujita K, Hiiragi T, Fujimoto K
and Tsukita S: Claudin-1 and -2: Novel integral membrane proteins
localizing at tight junctions with no sequence similarity to
occludin. J Cell Biol. 141:1539–1550. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furuse M and Tsukita S: Claudins in
occluding junctions of humans and flies. Trends Cell Biol.
16:181–188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Itallie CM and Anderson JM: Claudins
and epithelial paracellular transport. Annu Rev Physiol.
68:403–429. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiba H, Osanai M, Murata M, Kojima T and
Sawada N: Transmembrane proteins of tight junctions. Biochim
Biophys Acta. 1778:588–600. 2008. View Article : Google Scholar
|
|
11
|
Zihni C, Mills C, Matter K and Balda MS:
Tight junctions: From simple barriers to multifunctional molecular
gates. Nat Rev Mol Cell Biol. 17:564–580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sugimoto K and Chiba H: The
claudin-transcription factor signaling pathway. Tissue Barriers.
9:19081092021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J: Context-dependent roles of claudins
in tumorigenesis. Front Oncol. 11:6767812021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tabariès S and Siegel PM: The role of
claudins in cancer metastasis. Oncogene. 36:1176–1190. 2017.
View Article : Google Scholar
|
|
15
|
Sugimoto K, Ichikawa-Tomikawa N, Kashiwagi
K, Endo C, Tanaka S, Sawada N, Watabe T, Higashi T and Chiba H:
Cell adhesion signals regulate the nuclear receptor activity. Proc
Natl Acad Sci USA. 116:24600–24609. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kojima M, Sugimoto K, Tanaka M, Endo Y,
Kato H, Honda T, Furukawa S, Nishiyama H, Watanabe T, Soeda S, et
al: Prognostic significance of aberrant claudin-6 expression in
endometrial cancer. Cancers (Basel). 12:27482020. View Article : Google Scholar :
|
|
17
|
Kojima M, Sugimoto K, Kobayashi M,
Ichikawa-Tomikawa N, Kashiwagi K, Watanabe T, Soeda S, Fujimori K
and Chiba H: Aberrant claudin-6-adhesion signaling promotes
endometrial cancer progression via estrogen receptor α. Mol Cancer
Res. 19:1208–1220. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lal-Nag M and Morin PJ: The claudins.
Genome Biol. 10:2352009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sharma RK, Chheda ZS, Das Purkayastha BP,
Gomez-Gutierrez JG, Jala VR and Haribabu B: A spontaneous
metastasis model reveals the significance of claudin-9
overexpression in lung cancer metastasis. Clin Exp Metastasis.
33:263–275. 2016. View Article : Google Scholar
|
|
20
|
Liu H, Wang M, Liang N and Guan L:
Claudin-9 enhances the metastatic potential of hepatocytes via
Tyk2/Stat3 signaling. Turk J Gastroenterol. 30:722–731. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Higashi AY, Higashi T, Furuse K, Ozeki K,
Furuse M and Chiba H: Claudin-9 constitutes tight junctions of
folliculostellate cells in the anterior pituitary gland. Sci Rep.
11:216422021. View Article : Google Scholar
|
|
22
|
Mutch DG and Prat J: 2014 FIGO staging for
ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol.
133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Conlon N, Da Cruz Paula A, Ashley CW,
Segura S, De Brot L, da Silva EM, Soslow RA, Weigelt B and DeLair
DF: Endometrial carcinomas with a 'serous' component in young women
are enriched for DNA mismatch repair deficiency, lynch syndrome,
and POLE exonuclease domain mutations. Am J Surg Pathol.
44:641–648. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Köbel M, Ronnett BM, Singh N, Soslow RA,
Gilks CB and McCluggage WG: Interpretation of P53
immunohistochemistry in endometrial carcinomas: Toward increased
reproducibility. Int J Gynecol Pathol. 38(Suppl 1): S123–S131.
2019. View Article : Google Scholar
|
|
25
|
Nakano Y, Kim SH, Kim HM, Sanneman JD,
Zhang Y, Smith RJH, Marcus DC, Wangemann P, Nessler RA and Bánfi B:
A claudin-9-based ion permeability barrier is essential for
hearing. PLoS Genet. 5:e10006102009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sobel G, Németh J, Kiss A, Lotz G, Szabó
I, Udvarhelyi N, Schaff Z and Páska C: Claudin 1 differentiates
endometrioid and serous papillary endometrial adenocarcinoma.
Gynecol Oncol. 103:591–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szabó I, Kiss A, Schaff Z and Sobel G:
Claudins as diagnostic and prognostic markers in gynecological
cancer. Histol Histopathol. 24:1607–1615. 2009.PubMed/NCBI
|
|
28
|
Urick ME and Bell DW: Clinical
actionability of molecular targets in endometrial cancer. Nat Rev
Cancer. 19:510–521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cancer Genome Atlas Research Network;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stelloo E, Nout RA, Osse EM,
Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik
EM, Nijman HW, Putter H, Bosse T, et al: Improved risk assessment
by integrating molecular and clinicopathological factors in
early-stage endometrial cancer-combined analysis of the PORTEC
cohorts. Clin Cancer Res. 22:4215–4224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kommoss S, McConechy MK, Kommoss F, Leung
S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis
A, et al: Final validation of the ProMisE molecular classifier for
endometrial carcinoma in a large population-based case series. Ann
Oncol. 29:1180–1188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
León-Castillo A, de Boer SM, Powell ME,
Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock PM,
Bessette P, et al: Molecular classification of the PORTEC-3 trial
for high-risk endometrial cancer: Impact on prognosis and benefit
from adjuvant therapy. J Clin Oncol. 38:3388–3397. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vogel C and Marcotte EM: Insights into the
regulation of protein abundance from proteomic and transcriptomic
analyses. Nat Rev Genet. 13:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Edfors F, Danielsson F, Hallström BM, Käll
L, Lundberg E, Pontén F, Forsström B and Uhlén M: Gene-specific
correlation of RNA and protein levels in human cells and tissues.
Mol Syst Biol. 12:8832016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fortelny N, Overall CM, Pavlidis P and
Freue GVC: Can we predict protein from mRNA levels? Nature.
547:E19–E20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Paquet-Fifield S, Koh SL, Cheng L, Beyit
LM, Shembrey C, Mølck C, Behrenbruch C, Papin M, Gironella M,
Guelfi S, et al: Tight junction protein claudin-2 promotes
self-renewal of human colorectal cancer stem-like cells. Cancer
Res. 78:2925–2938. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reinhard K, Rengstl B, Oehm P, Michel K,
Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Wöll S, et al: An
RNA vaccine drives expansion and efficacy of claudin-CAR-T cells
against solid tumors. Science. 367:446–453. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kong FE, Li GM, Tang YQ, Xi SY, Loong JHC,
Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, et al: Targeting tumor
lineage plasticity in hepatocellular carcinoma using an anti-CLDN6
antibody-drug conjugate. Sci Transl Med. 13:eabb62822021.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Matsuzaki J, Lele S, Odunsi K and Tsuji T:
Identification of Claudin 6-specific HLA class I- and HLA class
II-restricted T cell receptors for cellular immunotherapy in
ovarian cancer. Oncoimmunology. 11:20209832022. View Article : Google Scholar : PubMed/NCBI
|
